

NLG Plenary Meeting Program Tuesday 6.11.2018



12.00-13.00 Registration (outside Meeting Room 180+181)

12.00-13.00 Lunch (Restaurant BM)

13.00-13.05 Welcome (Peter Brown)

Session I (Chaired by Mats Jerkeman)

13.05-14.30 Free papers :

- Sara Ekberg, Stockholm: Trends in the prevalence of Non-Hodgkin Lymphoma subtypes in Sweden 2000-2016
- Simon Husby, Copenhagen. Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Study
- Leo Meriranta, Helsinki: Clinical and Biological Features Behind Hallmark Aberrations in Diffuse Large B-cell Lymphoma
- Eivind Heggernes Ask, Oslo, Norway: Mass Cytometry and Serum Protein Profiling Reveal Disease-driven Systemic Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma
- Lasse Hjort Jakobsen, : Normalization of survival and minimal relapse risk after one year in adult Burkitt lymphoma patients treated with intensive immunochemotherapy: An international study of 159 real-world patients
- Roosa Prusila: Risk of secondary hematological malignancies after diagnosis of follicular lymphoma

14.30-15.30 Invited speaker: Liquid biopsy in lymphomas by Davide Rossi, Belinzona.

15.30-16.00 Coffee

Session II (Chaired by Sirpa Leppä)

16.00-16.30 Report from the Large Cell Group, Sirpa Leppä, Helsinki University Hospital

16.30-17.00 Report from the T-Cell group, Francesco d'Amore, Århus University Hospital

17.00-17.30 Report from the Mantle cell group, Mats Jerkeman, Lund University Hospital

17.30-18.00 Report from the Indolent group, Bjørn Østenstad, Oslo University Hospital

18.00-18.30 Business meeting

19.30 Dinner, Restaurant Treehouse, Bella Center

NLG Plenary Meeting Program

Wednesday 7.11.2018



Session III (Chaired by Karin Ekstrøm Smedby)

9.00-10.00 Abstracts and interesting cases

- Susanna Mannisto, Helsinki: Case: "All that shines..."
- Joachin Bæck, Ålborg, Denmark: Cumulative anthracycline exposure and risk of cardiotoxicity; A Danish nationwide cohort study of 2,440 lymphoma patients treated with or without anthracyclines.
- Tove Wästerlid, Stockholm, Sweden: Clinical Characteristics and Outcomes Among Very Elderly (≥ 85 years) Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study

10.00-10.30 Coffee

Session IV (Chaired by Peter Brown)

10.30-11.00 CNS-Group, Elisa Jacobsen-Pulczynski, Århus University Hospital

11.00-11.20 Hodgkin group, Alexander Fosså, Oslo University Hospital

11.20-11.45 Epidemiology Group, Karin Ekstrøm-Smedby, Stockholm University Hospital

11.45-12.00 PTLG Group, Harald Holte, Radiumhospitalet, Oslo

12.00-13.00 Lunch

Session V (Chaired by Arne Kolstad)

13.00-13.30 Pathology group, Marja-Liisa Karjalainen-Lindsberg, Helsinki University Hospital

Session VI (Chaired by Arne Kolstad)

13.30-15.00 Educational session "Controversies in treatment of indolent lymphoma". Bjørn Østenstad, Oslo University Hospital

15.00 Farewell

abbvie

 GILEAD
Advancing Therapeutics.
Improving Lives.

 JANSSEN-CILAG

SANOFI GENZYME 

AstraZeneca 



 NOVARTIS





KYOWA KIRIN



